Immunophenotypic Implications of Reverse-Circadian Glucocorticoid Treatment in Congenital Adrenal Hyperplasia

被引:0
|
作者
Nowotny, Hanna F. [1 ]
Choi, Hannah [1 ]
Ziegler, Selina [1 ]
Doll, Natalie [1 ]
Baeuerle, Ariane [1 ]
Welp, Ann-Christin [1 ]
Dubinski, Ilja [2 ]
Schiergens, Katharina [2 ]
Neumann, Uta [3 ]
Tschaidse, Lea [1 ]
Auer, Matthias K. [1 ]
Rothenfusser, Simon [4 ,5 ]
Schmidt, Heinrich [2 ]
Reisch, Nicole [1 ]
机构
[1] Ludwig Maximilians Univ Munchen, LMU Univ Hosp, Dept Med 4, D-80336 Munich, Germany
[2] Ludwig Maximilians Univ Munchen, LMU Univ Hosp, Dr Von Hauner Childrens Hosp, Dept Pediat, D-80336 Munich, Germany
[3] Charite Univ Med Berlin, Klin Padiatr Endokrinol & Diabetol, D-13353 Berlin, Germany
[4] Ludwig Maximilians Univ Munchen, LMU Univ Hosp, Div Clin Pharmacol, D-80337 Munich, Germany
[5] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth Neuherberg, Einheit Klin Pharmakol EKLiP, D-85764 Oberschleissheim, Germany
关键词
circadian; glucocorticoids; immunophenotype; congenital adrenal hyperplasia; MODIFIED-RELEASE HYDROCORTISONE; REGULATORY T-CELLS; CHILDREN; IDENTIFICATION; INSUFFICIENCY; MORTALITY; THERAPY; HEALTH; ADULT; SLEEP;
D O I
10.3390/ijms26041479
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH) requires lifelong glucocorticoid replacement to manage cortisol deficiency and excessive androgen production. Conventional circadian treatment (CT) tries to mimic natural cortisol rhythms, whereas reverse-circadian treatment (RC) prioritizes the suppression of adrenal androgen excess overnight through evening dosing. Limited data exist on the immunological impact of these regimens. A bi-centric study was conducted, including 41 pediatric and adolescent CAH patients. Peripheral blood samples were collected from patients on conventional treatment (n = 38) or RC (n = 16), with 11 RC patients switching to conventional treatment. Immune cell phenotypes, cytokine profiles, and natural killer (NK) cell cytotoxicity were assessed. Patients receiving RC showed lower percentages of CD4+CD25+ T cells (p = 0.0139). After the switch, patients with RC presented with a higher percentage of non-classical monocytes (p = 0.0255) and a lower percentage of Th17 cells (p = 0.0195). A lower expression of CD107 was observed with RC (p < 0.0001), as well as a higher percentage of NKp30 (p = 0.0189). Comparing patients after the switch from RC to HC, patients with RC presented with a lower NKG2D expression (p = 0.0420). Both conventional treatment and RC exhibited distinct immunological impacts, with CT showing modest advantages in normalizing immune phenotypes. These findings suggest that CT may offer immunological benefits for managing young patients with congenital adrenal hyperplasia.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] New approaches to the treatment of congenital adrenal hyperplasia
    Merke, DP
    Cutler, GB
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (13): : 1073 - 1076
  • [42] TREATMENT OF CONGENITAL ADRENAL-HYPERPLASIA IN MEN
    KIRKLAND, RT
    KEENAN, BS
    HOLCOMBE, JH
    KIRKLAND, JL
    CLAYTON, GW
    NEW ENGLAND JOURNAL OF MEDICINE, 1979, 300 (17): : 988 - 989
  • [43] Antenatal diagnosis and treatment of congenital adrenal hyperplasia
    New M.I.
    Current Urology Reports, 2001, 2 (1) : 11 - 18
  • [44] Pathophysiology and Treatment of Congenital Adrenal Hyperplasia (CAH)
    Kapelari, K.
    AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2011, 4 (02): : 28 - 34
  • [45] Toward better treatment of congenital adrenal hyperplasia
    Speiser, PW
    CLINICAL ENDOCRINOLOGY, 1999, 51 (03) : 273 - 274
  • [46] Surgical treatment of congenital adrenal hyperplasia with adenoma
    Kong, Weihao
    Shi, Yihui
    Gong, Zhicong
    Yang, Delin
    ASIAN JOURNAL OF SURGERY, 2024, 47 (12) : 5464 - 5464
  • [47] TREATMENT OF CONGENITAL ADRENAL-HYPERPLASIA INUTERO
    SHULMAN, DI
    MUELLER, OT
    GALLARDO, LA
    STIFF, D
    OSTRER, H
    CLINICAL RESEARCH, 1989, 37 (02): : A832 - A832
  • [48] MONITORING TREATMENT IN CONGENITAL ADRENAL-HYPERPLASIA
    APPAN, S
    HINDMARSH, PC
    BROOK, CGD
    ARCHIVES OF DISEASE IN CHILDHOOD, 1989, 64 (09) : 1235 - 1239
  • [49] DEXAMETHASONE TREATMENT FOR CONGENITAL ADRENAL-HYPERPLASIA
    YOUNG, MC
    HUGHES, IA
    ARCHIVES OF DISEASE IN CHILDHOOD, 1990, 65 (03) : 312 - 314
  • [50] DIAGNOSIS AND TREATMENT OF CONGENITAL VIRILIZING ADRENAL HYPERPLASIA
    WILKINS, L
    POSTGRADUATE MEDICINE, 1961, 29 (01) : 31 - &